Drugs Losing Exclusivity in 2029 & Key Intermediates
20 drugs expire in 2029 (public sources), 19 with recorded synthesis routes; key intermediates of 19 drugs are already available through the Unibest supply network. Generic developers typically secure intermediate supply 2–3 years ahead — use this table for shortlisting and RFQ.
| Drug | Tier | Expiry | Indications | Routes | CAS count | Available |
|---|---|---|---|---|---|---|
| 替格瑞洛 Ticagrelor | B · Position early | 2029 | 中风、急性冠脉综合征、心肌梗塞 | 5 | 55 | Available ×55 |
| 卡非佐米 Carfilzomib | B · Position early | 2029 | 多发性骨髓瘤 | 3 | 29 | Available ×29 |
| 硫酸艾沙康唑 Isavuconazonium Sulfate | C · Watch | 2029 | 毛霉菌目感染、曲霉菌属感染、隐孢子虫感染 | 1 | 22 | Available ×22 |
| 苹果酸卡博替尼 Cabozantinib S-malate | B · Position early | 2029 | 神经内分泌瘤、胰腺神经内分泌肿瘤、肾细胞癌 | 3 | 21 | Available ×21 |
| 利格列汀 Linagliptin | C · Watch | 2029 | 二型糖尿病 | 4 | 21 | Available ×21 |
| 醋酸伏诺拉生 Vonoprazan Acetate | C · Watch | 2029 | 消化性溃疡出血 | 4 | 20 | Available ×20 |
| 阿贝西利 Abemaciclib | A · Act now | 2029 | 乳腺癌 | 2 | 15 | Available ×15 |
| 琥珀酸瑞波西利 Ribociclib Succinate | A · Act now | 2029 | 乳腺癌 | 1 | 14 | Available ×14 |
| 甲磺酸达拉非尼 Dabrafenib Mesylate | B · Position early | 2029 | 甲状腺瘤、结直肠癌、胶质瘤 | 2 | 12 | Available ×12 |
| 曲美替尼 Trametinib | C · Watch | 2029 | 甲状腺瘤、胶质瘤、毛细胞白血病 | 1 | 13 | Available ×6 |
| 布瑞哌唑 Brexpiprazole | A · Act now | 2029 | 精神分裂症、阿尔茨海默病、躁动 | 3 | 12 | Available ×4 |
| 卡利拉嗪盐酸盐 Cariprazine Hydrochloride | A · Act now | 2029 | 重度抑郁症、精神分裂症、躁狂症 | 3 | 21 | Available ×4 |
| 盐酸艾司氯胺酮 Esketamine Hydrochloride | B · Position early | 2029 | 重度抑郁症、自杀意念、抑郁症 | 8 | 36 | Available ×3 |
| 酒石酸匹莫范色林 Pimavanserin Tartrate | C · Watch | 2029 | 妄想、幻觉 | 2 | 14 | Available ×3 |
| 德拉沙星 Delafloxacin | C · Watch | 2029 | 社区获得性细菌肺炎、社区获得性肺炎、细菌性皮肤疾病 | 2 | 8 | Available ×3 |
| 米拉贝隆 Mirabegron | B · Position early | 2029 | 神经性膀胱功能障碍、膀胱过度活动症 | 7 | 36 | Available ×1 |
| 阿吡利塞 Alpelisib | C · Watch | 2029 | 生长障碍、遗传病、PIK3CA相关生长过度谱系 | 2 | 17 | Available ×1 |
| 泰地唑利磷酸盐 Tedizolid Phosphate | C · Watch | 2029 | 皮肤和皮肤结构感染、葡萄球菌感染、细菌性皮肤疾病 | 3 | 22 | Available ×1 |
| 可美替尼 Cobimetinib Fumarate | C · Watch | 2029 | 黑色素瘤 | 3 | 30 | Available ×1 |
| 卡格列净/盐酸二甲双胍 Canagliflozin/Metformin Hydrochloride | B · Position early | 2029 | 终末期肾脏病、心脏和血管疾病、腹主动脉瘤 | - | - | - |
Frequently asked questions
Which drugs lose exclusivity in 2029?
20 drugs expire in 2029 per public sources: Abemaciclib, Ribociclib Succinate, Cabozantinib S-malate, Ticagrelor, Canagliflozin/Metformin Hydrochloride, Linagliptin, etc.
When should we start sourcing intermediates for 2029 launches?
Generic developers typically secure development-scale supply 2–3 years before expiry. 19 of the 20 drugs in this table already have on-sale intermediates in the Unibest network; the rest can be RFQ'd per CAS.
Are route and CAS data verified?
All fields are structured data cross-verified from public sources; intermediates carry registry codes and CAS numbers, and every "Available" badge links to real listings.
Source: cross-verified structured fields · Expiry years are public-source estimates; consult individual agencies for authoritative dates · 2026-09-24